Tamoxifen, Endoxifen, and CYP2D6: The Rules for Evaluating a Predictive Factor The Kuderer/Peppercorn Article Reviewed

被引：0
|
作者：
Goetz, Matthew P. [1 ,2 ]
机构：
[1] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Pharmacol, Rochester, MN USA
来源：
ONCOLOGY-NEW YORK | 2009年 / 23卷 / 14期
关键词：
BREAST-CANCER; WOMEN; THERAPY; ADHERENCE; BIOTRANSFORMATION; ANASTROZOLE; METABOLISM; GENOTYPE; OUTCOMES;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1233 / 1236
页数：3
相关论文
共 50 条
  • [21] Optimized CYP2D6 phenotype assignment for plasma endoxifen prediction in breast cancer patients treated with tamoxifen
    Schroth, Werner
    Winter, Stefan
    Eichelbaum, Michel
    Muerdter, Thomas
    Schwab, Matthias
    Brauch, Hiltrud
    CANCER RESEARCH, 2017, 77
  • [22] Simplified CYP2D6 metabolizer phenotype categorization of patients treated with tamoxifen: Role for endoxifen level monitoring?
    Lee, Clara Inkyung
    Low, Amanda Siew Kee
    Fox, Peter
    Balakrishnar, Bavanthi
    Balleine, Rosemary L.
    Gao, Bo
    Provan, Pamela
    Coulter, Sally
    Liddle, Christopher
    Hui, Rina
    Wilcken, Nicholas
    Wong, Mark
    Gurney, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen
    Stearns, V
    Hayes, DF
    Jin, Y
    Ullmer, L
    Nguyen, A
    Storniolo, AM
    Flockhart, U
    Desta, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 5S - 5S
  • [24] Prospective Assessment of CYP2D6 by Genotyping, Phenotyping and Measurement of Tamoxifen, 4-Hydroxy-Tamoxifen and Endoxifen in Breast Cancer Patients Treated with Tamoxifen
    Zaman, K.
    Dahmane, E.
    Csajka, C.
    Perey, L.
    Buclin, T.
    Bodmer, A.
    Leyvraz, S.
    Rindisbacher, M. Galmiche
    Berthod, G.
    Chin, E.
    Decosterd, L.
    CANCER RESEARCH, 2010, 70
  • [25] Tamoxifen, HER2, and Endoxifen: The Role of CYP2D6 as a Predictor of Tamoxifen Resistance in ER+/HER2+Breast Cancer
    Goetz, M. P.
    Reinicke, K. E.
    Reid, J. M.
    Suman, V. J.
    Kuffel, M. J.
    Safgren, S. L.
    Buhrow, S. A.
    Reynolds, C. A.
    Jenkins, R. B.
    Hawse, J. R.
    Perez, E. A.
    Ingle, J. N.
    Ames, M. M.
    CANCER RESEARCH, 2009, 69 (24) : 594S - 594S
  • [26] CYP2D6 polymorphisms associated with tamoxifen outcome
    Hutchinson L.
    Nature Reviews Clinical Oncology, 2009, 6 (12) : 675 - 675
  • [27] CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
    V. O. Dezentjé
    F. L. Opdam
    H. Gelderblom
    J. Hartigh den
    T. Van der Straaten
    R. Vree
    E. Maartense
    C. H. Smorenburg
    H. Putter
    A. S. Dieudonné
    P. Neven
    C. J. H. Van de Velde
    J. W. R. Nortier
    H.-J. Guchelaar
    Breast Cancer Research and Treatment, 2015, 153 : 583 - 590
  • [28] CYP2D6 Polymorphisms and the impact on tamoxifen therapy
    Beverage, Jacob N.
    Sissung, Tristan M.
    Sion, Amy M.
    Danesi, Romano
    Figg, William D.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (09) : 2224 - 2231
  • [29] Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
    Sideras, Kostandinos
    Ingle, James N.
    Ames, Matthew M.
    Loprinzi, Charles L.
    Mrazek, David P.
    Black, John L.
    Weinshilboum, Richard M.
    Hawse, John R.
    Spelsberg, Thomas C.
    Goetz, Matthew P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2768 - 2776
  • [30] Tamoxifen, Antidepressants, and CYP2D6: The Conundrum Continues
    Holzman, David
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (20) : 1370 - 1371
12345